Sanxin Medtec(SZ:300453) Zheng Quan Zhi Xing·2025-08-26 16:40Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. has announced the lifting of restrictions on the first phase of its 2024 restricted stock incentive plan, allowing for the circulation of 52,239,752.5 shares, which accounts for 0.7369% of the total shares [1] Summary by Sections Incentive Plan Approval Process - The company held meetings to approve the relevant proposals related to the 2024 restricted stock incentive plan, including the draft and management measures [1][2][3] - The independent directors collected proxy votes from shareholders for the incentive plan, which was approved at the 2024 first extraordinary general meeting [3] Conditions for Lifting Restrictions - The first lifting of restrictions will occur on September 1, 2025, following the completion of the stock grant registration on August 30, 2024 [5] - The board confirmed that the conditions for lifting restrictions have been met, including no negative audit opinions and compliance with legal regulations [5][6] Performance Targets - The company achieved a net profit of 209.8692 million yuan for 2024, a 15.35% increase from 2023, meeting the performance targets set for the incentive plan [8] - The revenue for 2024 was reported at 1,500.4384 million yuan, reflecting a growth of 15.41% compared to the previous year [8] Stock Circulation Arrangement - A total of 112 individuals will have their restricted stocks lifted, with 384.9575 million shares available for circulation, representing 48.45% of the total granted shares [10] - The stock lifting will include 6 directors and senior management, who will have 50% of their granted shares released [10] Changes in Stock Structure - Following the lifting of restrictions, the total share capital remains at 522,397,525 shares, with no shares under restriction [12][13] - The company will repurchase and cancel a total of 313,250 shares due to non-compliance with lifting conditions by some incentive recipients [12]